GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results

LONDON, July 21, 2010 - In an interview with financial broadcaster www.cantos.com,
GlaxoSmithKline CEO Andrew Witty says one-offs held back sales growth in Q2
but highlights the strong underlying performance of Emerging Markets,
Consumer and Vaccines.

The Pharma boss also points to "an unprecedented" five new drugs in late
stage trials as a sign of the successful restructuring of the group.

Mr Witty tackles the ongoing Avandia controversy and the recent GBP1.6bn
payout, saying "it was actually in the best interest of the company's
shareholders."

The interview and transcript are available now on
www.cantos.com/company/GlaxoSmithKline.

Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email amanda.alexander@cantos.com or phone
+44-207-936-1352.

If you would like to contact us, please email amanda.alexander at cantos.com or phone +44-207-936-1352.